![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, July 02, 2017 2:16:21 PM
"Companies involved in the management of chronic pain have been quick to involve themselves in the recent shift to a new direct-to-consumer process. There are four products now on the market for OTC pain management. Two global companies Bayer (Aleve) and Sanofi (Icy-Hot) and two smaller, public companies, NeuroMetrix (Quell) and BioElectronics (ActiPatch). This market is sure to grow as the more consumers turn to opiate-free alternatives to pain management."
"Company: BioElectronics Corp. (OTC BIEL)
Technology: Pulse Short Wave Therapy
Another noteworthy firm in the pain management space is BioElectronics. In February, the company received over- the-counter FDA clearance and are now marketing their product, the Actipatch. Testing faired very well at delivering nagging pain relief to at least one pain subject that had had little result from other attempts at troublesome pain. The device (which retails for $30) delivers 720 hours of pain relief through pulse short wave therapy.
BioElectronics was founded in 2003, and with just $2 million in sales in 2016, the company expects sales to reach $5 million this year 2017 and $20 million the following year. Bio’s share price on the OTC exchange is .00085 with 12.6 billion shares outstanding and as a pink sheet listed-company, unaudited financials. Their market capitalization is $43 million, though the company is now in the process of raising capital. Similar to NueroMetrix, Bio identifies its major barrier in obtaining capital as the high cost of marketing."
http://www.onemednews.com/2017/05/11/electroceuticals/
This is a great article, but the author failed to mention that the Actipatch is the only unique and cheapest technology offered in the market place. The mechanism of action and fundamental technology principles are different from other existing products. Aleve, ICy-Hot and Quell are all Transcutaneous Electrical Nerve Stimulator (TENS), while the Actipatch is a pulsed elecromagnetic field (PEMF) device that neuromodulates nerve activities to reduce pain, and it is the first in its class to be cleared by the FDA.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K152432
PQY Classification
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?ID=5031
Alliance Creative Group (ACGX) Releases Q2 2024 Financial and Disclosure Report with an increase of over $130,000 in Net Income from Q2 2023 to Q2 2024 • ACGX • Aug 14, 2024 8:30 AM
Avant Technologies Unveils AI-Powered Healthcare Infrastructure to Deliver Intelligent Healthcare Solutions • AVAI • Aug 14, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q2 FY2024 Financial Results • SNWV • Aug 13, 2024 7:11 AM
Kona Gold Beverages, Inc. Nears Completion of Reverse Merger with New Candidate • KGKG • Aug 12, 2024 10:00 AM
Maybacks Global Entertainment and DigiTrax Entertainment Sign Agreement to Broadcast "Karaoke Cloud" on iDreamCTV • AHRO • Aug 12, 2024 8:45 AM
HealthLynked Partners with RxSpark to Enhance Medication Access and Management for Patients • HLYK • Aug 12, 2024 8:00 AM